Boston—While checkpoint inhibitors may be stealing the cancer news spotlight these days, advances in chimeric antigen receptor–modified T-cell therapy (CAR therapy) also have immuno-oncology investigators excited.
“Hopefully, we will see approvals for hematologic T-cell–based therapies in the next two years,” said Michel Sadelain, MD, PhD, the director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center (MSKCC), in New York City.
Several CAR